Life Sciences Mergers & Acquisitions (M&A)

by Enal S. Razvi, Ph.D. and Jonathan Burbaum, Ph.D.

Published: April, 2006

Recently, there has been an upsurge in the number of mergers & acquisitions (M&A) in the life sciences space. According to D&MD's new market analysis report, the life sciences space will continue to see consolidation in 2006 and beyond.

D&MD's Life Sciences Mergers & Acquisitions (M&A): A Reference Guide Illustrating Recent Trends in Life Science M&A market analysis report focuses on mergers & acquisitions (M&A) in the general life sciences space. This report is an excellent reference guide for the life sciences audience engaged primarily in drug discovery and development.

The report includes information on the latest industry statistics on recent life sciences merger and acquisition transactions in biotechnology and medical devices, latest industry statistics on initial public offerings (IPOs) and venture capital investing. Specifically, key merger and acquisition transactions within the last 18 months in the life sciences tools space are presented and characterized in this report to help readers spot growth trends or define exit strategies.

The authors of this report rely on experience to define and illustrate key components of a merger and acquisition transaction.

Companies seeking to contemplate a transaction should purchase this report and use as a reference guide to evaluate opportunities. Analyze this data to get a feel for the landscape and take the appropriate steps to explore a merger and acquisition transaction.

Buy this report to:

> Utilize as a reference guide of Life Sciences M&A transactions. The report is designed as a handbook for biotechnology firms especially the smaller-sized ones who are potentially exploring an M&A transaction, and seek to review the landscape.

> Examine a highly quantitative resource that provides the latest statistics on the life science M&A space, IPO space and venture capital (VC) financing space including statistics on pre- and post-money values of IPO transactions (illustrating an exit option) and compares these with M&A transactions as another exit option.

> Explore quantitative analysis and figures that illustrate the M&A trends and can be used in investor, partnering, and board-level presentations when discussing a potential M&A transaction.

> Gain exclusive statistics and analysis not available to the general biotechnology community.

Questions answered:

> What are the recent qualitative and quantitative trends in life sciences M&A transactions?

> How is the IPO market compared to the M&A market as an exit strategy?

> What factors to consider when contemplating an M&A transaction in the life sciences space?

> What are the venture capital investment trends in life sciences companies recently?

Core opportunities addressed in the life sciences M&A space:

> Small biotechnology companies need scale, and one way to achieve this is via consolidation-mergers or acquisitions.

> Many biotechnology companies are incapable of going public-their focus, size, revenues, team, and core technology/capability is unable to excite and sustain a public company. Therefore, one exit strategy for these companies is to merge into another company or be acquired.

> Service providers-such as advisory companies, strategic planning outfits, law firms-will find this reference guide valuable.

Chapter Summary

1 Executive Summary

2 Venture Capital Investment Trends in Life Science Companies

3 Recent M&A Transactions in the Life Sciences Space

4 Qualitative and Quantitative Analysis of M&A in Life Sciences

5 References and Further Sources of Information

Format: PDF
Price: $895.00 / GBP447.50